However, in lung cancer, lidocaine with a higher concentration (8 mM) was required to promote miR-539, inhibit the expression of EGFR as well as its ERK (extracellular regulated protein kinases), and the PI3K/Akt signal pathway to play its role in inhibiting the proliferation, migration, and invasion of tumor cells (103, 104). Here, EGFR is linked to lung carcinoma.